- Health Canada approved Lilly’s Mounjaro (tirzepatide) for children and adolescents aged 10–17 years with type 2 diabetes as an adjunct to diet and exercise.
- The approval is based on the SURPASS-PEDS Phase III trial, where Mounjaro significantly improved HbA1c and BMI versus placebo.
- Patients receiving Mounjaro (pooled 5 mg and 10 mg doses) achieved an average 2.0% reduction in HbA1c and an 8.9% reduction in BMI at 30 weeks, with a safety profile consistent with adults.
- The expanded indication offers a new treatment option for youth-onset type 2 diabetes, a more aggressive form of the disease with limited effective therapies.
Takeaways:
Lilly now offers Canadian pediatric endocrinologists a once‑weekly injectable that addresses both glycemic control and weight – two core drivers of aggressive youth‑onset type 2 diabetes where metformin and basal insulin often fall short. This expands Lilly’s franchise beyond adult type 2 diabetes into pediatric care, differentiates Mounjaro from older drugs that lack meaningful BMI lowering in teens.
Source: CA Newswire
